At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 773 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Axial Spondyloarthritis. Completed, enrolled 773 participants across 127 sites in 23 countries.
Detailed Summary
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
CountriesArgentina, Austria, Brazil, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionMay 2020
Study CompletionMay 2021
TodayJul 2026
First PostedApr 26, 2017
Enrollment StartMay 9, 2017
Primary CompletionMay 26, 2020
Study CompletionMay 27, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.2 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC